Role of perioperative chemotherapy for high-grade synovial sarcoma: a retrospective study of a single Asian cohort in China

Role of perioperative chemotherapy for high-grade synovial sarcoma: a retrospective study of a single Asian cohort in China | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Role of perioperative chemotherapy for high-grade synovial sarcoma: a retrospective study of a single Asian cohort in China Qiaowei Lin, Peihang Xu, Zhengwang Sun, Lin Yu, Chunmeng Wang, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-2054776/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background Synovial sarcoma (SS) is an aggressive but chemosensitive soft tissue sarcoma. However, there are scarce data about the benefit of perioperative chemotherapy in high-grade SS patients. This study aimed to explore important prognostic factors and clinical efficacy of perioperative chemotherapy in high-grade SS patients. Methods This study included 143 high-grade SS patients who underwent curative surgery in Shanghai Cancer Center, Fudan University between 2006 and 2020. Univariate and multivariate analyses were performed to identify independent prognostic predictors. The effects of perioperative chemotherapy on overall survival (OS) or time to recurrence (TTR) were evaluated by Kaplan-Meier curves. Results Among 143 patients, pre- and post-operative chemotherapy were delivered in 17 cases and 88 cases, respectively. Kaplan-Meier curves did not identify obvious differences in OS or TTR concerning perioperative chemotherapy. However, there is a trend towards better OS and TTR in patients receiving preoperative chemotherapy. The corresponding TTR or OS probabilities at 5-year were 49.9%, and 84.4%, respectively in patients with preoperative chemotherapy while 36.2%, and 56.6%, respectively in patients without. Multivariate analyses identified age and tumor size as independent factors for TTR while tumor size and necrosis were independent predictors for worse OS. Conclusions High-grade SS patients might benefit from preoperative chemotherapy but not postoperative chemotherapy. Tumor size, age and necrosis were important factors influencing patients’ prognosis. Synovial sarcoma chemotherapy overall survival time to recurrence prognosis Figures Figure 1 Background Synovial sarcoma (SS), which is an aggressive soft tissue sarcoma (STS), accounts for 5%-10% of all STS( 1 ). It prefers to occur at a younger mean age of onset, especially adolescents and young adults, which is unique from other STS( 2 ). Pathologically, SS can be divided into three histologic subtypes: monophasic type, biphasic type, and poorly differentiated type. Genetically, it possesses a constant chromosomal translocation between chromosomes 18 and X in greater than 95% cases, leading to the expression of different SS18: SSX oncogenic fusion proteins( 2 , 3 ). Despite its name, SS is not derived from synovial tissues. It can occur anywhere in the body, with a predilection for the extremities of young adults, frequently seen in soft tissues around the joint( 4 , 5 ). Generally, this high-grade sarcoma is characterized by high potentials of developing recurrence and metastasis, 70% to the lung and 10 ~ 20% to the bone( 2 , 6 , 7 ). 5-year survival rate for children and adolescents were reported to be 83% compared to 62% in adults by utilizing registry data( 4 ). Similarly, Smolle et al. demonstrated an 89% 5-year cancer specific survival rate in children compared to 75% in adults( 5 ). Wide surgical resection, complemented by radiotherapy in cases of large tumors or invaded margins, remains the mainstay treatment options for localized SS( 8 ). Similar to other high-grade STS subtypes, in order to decrease the risk of local recurrence and distant metastasis due to the existence of subclinical micrometastasis, perioperative chemotherapy is commonly considered as a rational approach for high-grade SS( 9 ). However, though SS is considered a relatively chemosensitive tumor compared with other STS, there are only scarce and conflicting researches about the benefit of perioperative chemotherapy in patients with high-grade SS( 10 ). In 2007, Eilber et al. demonstrated that ifosfamide-based chemotherapy was associated with an improved disease-specific survival (DSS) in adult patients with primary, extremity, high-risk SS( 11 ). However, contrary to this, the French Sarcoma Group observed no overall survival (OS) benefit with perioperative chemotherapy in adult SS patients( 12 ). Nevertheless, this study included patients carrying low-risk tumor characteristics in which chemotherapy is unlikely to be of benefit. Therefore, our research was conducted to clarify the role of perioperative chemotherapy in high-grade SS patients and to identify independent prognostic factors for SS. To this aim, 143 patients with resectable high-grade SS in our single cancer center were retrospectively reviewed and enrolled in. Materials And Methods Patients From 2006 to 2020, 143 patients who underwent curative resections and diagnosed as G3 SS in our cancer center were retrospectively reviewed and enrolled in this study. The inclusion criteria were as follows: 1) Locally resectable tumors; 2) R0 resections; 2) No metastatic tumors of lung; 3) Histologically diagnosed as SS; 4) No secondary tumor; 5) French Federation Nationale des Centres de Lutte Cotre le Caner (FNCLCC) classification of grade 3; 6) Complete clinicopathologic information and follow-up information. Informed signed written consents were obtained from patients and/or their legal guardians. Ethical approval was obtained from the Research Ethics Committee of Shanghai Cancer Center (050432-4-2108). Pathological examinations Two independent pathologists (Lin Yu and Qifeng Wang), who were specialized in diagnosing STS in our cancer center, reviewed the pathological slides through microscope and confirmed the pathological diagnosis of SS. The following pathological characteristics, such as tumor location, tumor size, histologic type, incisal margin, necrosis, vessel infiltration, invasive depth, Ki-67 proliferative index, SS18 conditions, and FNCLCC classification were recorded for further analysis. Follow-up data We achieved our follow-up data through telephones and electronic medical records of our center. We ended our followed up in December 2021. Two endpoints were set in our study, that were OS, which was defined as the interval from the date of surgery to death from any cause or last follow-up time, and time to recurrence (TTR), which was calculated from the date of surgery to the date of recurrence or last follow-up time. The administration of chemotherapy The patients with perioperative chemotherapy received an anthracycline- and ifosfamide-containing (IA) regimen: ifosfamide 1.8g/m 2 /d from day 1 to day 5 plus doxorubicin 60mg/m 2 /d short infusion on day 1 every 21 days. The patients with preoperative chemotherapy received chemotherapy for about 2 to 3 treatment courses before surgery, approximately 0 or 5 to 6 treatment courses after surgery. As for the patients with postoperative chemotherapy, approximately 1 month after surgery, we performed IA regimen on them, who received about 5 to 6 treatment courses. Statistical analysis OS and TTR were assessed by Kaplan‑Meier curves with 95% confidence intervals (CIs) for SS patients underwent curative surgeries. Differences between OS and TTR were compared using the log‑rank test. Univariate and multivariate analyses were carried out by Cox regression analysis. Variables significantly associated with OS or TTR in the univariate analysis were incorporated into multivariate analyses to identify independent prognostic factors. Pearson chi-square test was used to analyze the relationship between patients with chemotherapy and without chemotherapy concerning clinicopathologic characteristics and Fisher’s exact test was used when necessary. All statistical analyses were performed using IBM SPSS Statistics 23 (SPSS Inc., Armonk, NY, USA). p -value <0.05 was considered statistically significant. Results Patient characteristics From 2006 to 2020, 143 patients who underwent curative surgery and been diagnosed as high-grade SS in Shanghai Cancer Center, Fudan University were included in our analysis. Detailed clinical characteristics were shown in Table 1 . There were 75 males and 68 females with an average age of 36.7 years (range 15-71 years) in this study. 85 patients were older than 30 years old at the time of initial diagnosis. The tumor sites of involvement were mostly in the extremities and trunks (n=130). Overall, the average size of the tumors was 6.8cm (range 1-23cm). 88 patients had tumors larger than 5cm. The distributions of the histology type were as follows: monophasic type 96 cases, biphasic type 37 cases, and poorly differentiated type 10 cases. Necrosis and vessel infiltration could be detected in 58 and 16 patients, respectively. With regard to invasive depth, the majority of tumors infiltrated to muscles (n=115), followed by viscera (n=16) and superficial tissues (n=11). At the end of follow-up period, 84 patients suffered from postoperative local recurrence or distant metastasis while 52 patients died from SS or other reasons. Among 143 patients, pre- and post-operative chemotherapy were delivered in 17 cases (12%) and 88 cases (62%), respectively ( Table 1 ). 13 patients received both pre- and post-operative chemotherapy. Clinicopathologic characteristics were not significantly different between patients with chemotherapy and those without ( Table 2 and Table 3 ). Kaplan-Meier curves of TTR and OS Kaplan-Meier curves were performed to evaluate the prognostic values of perioperative chemotherapy in high-grade SS patients. However, we did not see any significant differences in OS or TTR with regard to the status of perioperative chemotherapy (Figure 1). Although preoperative chemotherapy did not reach statistical significance, there was a trend that patients with preoperative chemotherapy had better OS and TTR than those without in the long term (Figure 1A and 1B). The 3-year and 5-year TTR rates of the patients receiving preoperative chemotherapy were 49.9% (95% CI 24.6% to 75.2%) and 49.9% (95% CI 24.6% to 75.2%), respectively, and that of the patients receiving non-preoperative chemotherapy were 45.3% (95% CI 36.5% to 54.1%) and 36.2% (95% CI 27.2% to 45.2%), respectively. The corresponding OS probabilities at 3-year and 5-year were 84.4% (95% CI 64.0% to 104.8%), 84.4% (95% CI 64.0% to 104.8%), respectively in the preoperative chemotherapy group while 66.8% (95% CI 58.2% to 75.4%), 56.6% (95% CI 47.0% to 66.2%), respectively in the non-preoperative chemotherapy group. As for postoperative chemotherapy, we observed that the 3-year and 5-year TTR rates of the patients with it were 47.6% (95% CI 36.8% to 58.3%) and 36.6% (95% CI 25.2% to 48.0%), respectively, and that of the patients without it were 43.2% (95% CI 30.1% to 56.3%) and 38.1% (95% CI 24.8% to 51.4%), respectively. The corresponding OS probabilities at 3-year and 5-year were 66.3% (95% CI 55.7% to 76.9%), 59.2% (95% CI 47.6% to 70.8%), respectively in the postoperative chemotherapy group while 70.7% (95% CI 58.2% to 83.2%), 57.4% (95% CI 42.7% to 72.1%), respectively in the non-postoperative chemotherapy group. Univariate and multivariate analyses of SS patients Univariate and multivariate analyses were performed to explore the independent prognostic factors for OS and TTR in SS. In the univariate analysis, age ≥ 30 years, deep locations, tumor size ≥ 5cm, necrosis and Ki-67 proliferative index ≥ 50% were adverse prognostic factors for both OS ( Table 4 ) and TTR ( Table 5 ). Besides, patients without vessel infiltration had a favorable outcome for OS ( Table 4 ). Further multivariate analyses identified tumor size (HR: 2.194, p = 0.030) and necrosis (HR: 2.204, p = 0.009) as independent prognostic factors for OS ( Table 4 ). Meanwhile, age (HR: 2.028, p = 0.004) and tumor size (HR: 2.011, p = 0.005) were highly significant independent predictors of worse TTR ( Table 5 ). Discussion Generally, SS is considered a high-grade sarcoma, marked by a poor prognosis, with an expected 5-year OS in adult patients ranging from 50–60% and a 5-year metastatic disease-free survival (DFS) ranging from 40–60%( 11 ). There has been a trend for improved survival over time with early cohorts from the 1960s quoting a 25–51% 5-year OS rate( 1 ). However, due to its rarity, the knowledge about SS is usually restricted in small single-center analysis, resulting in uncertainty about the optimal treatments for them. Till today, though SS is thought to be a kind of chemosensitive sarcoma, it remains challenging to accurately assess the function of perioperative chemotherapy in high-grade SS patients( 13 ). To elucidate the role of perioperative chemotherapy and to clarify important clinicopathological characteristics in high-grade SS, 143 SS patients underwent curative surgeries in our cancer center were retrospectively reviewed and enrolled in this research. Among them, preoperative chemotherapy was delivered in 17 cases while postoperative chemotherapy was performed in 88 cases. Anthracycline-based chemotherapy is the conventional first line for advanced STS. As the antitumor efficacy of ifosfamide is well known in SS, the regimen of anthracycline plus ifosfamide is commonly suggested for SS patients( 14 – 16 ). Conclusions concerning the function of perioperative chemotherapy vary greatly, possibly because it is difficult to conduct a prospective study on the effect of perioperative chemotherapy, specifically for this tumor type( 17 ). In 2007, after retrospectively analyzing 101 adult SS patients, researchers from Memorial Sloan Kettering Cancer Center concluded that ifosfamide-based chemotherapy improved DSS in adult patients with high-risk, primary, extremity, SS( 11 ). The 4-year DSS for patients treated with ifosfamide and doxorubicin was 88%, compared with 67% for patients in the control arm. However, by contrast, we did not see significant differences in OS or TTR between patients with perioperative chemotherapy and patients without. There was a trend towards better OS and TTR for patients receiving preoperative chemotherapy in the long term. This phenomenon might partly be explained by the sample size as we only had 17 patients receiving preoperative chemotherapy, which was hard for us to draw a definitive conclusion. The 5-year TTR or OS rates of the patients receiving preoperative chemotherapy were 49.9% (95% CI 24.6–75.2%), and 84.4% (95% CI 64.0–104.8%), respectively, and that of the patients receiving non-preoperative chemotherapy were 36.2% (95% CI 27.2–45.2%), and 56.6% (95% CI 47.0–66.2%), respectively. The corresponding TTR or OS probabilities at 5-year were 36.6% (95% CI 25.2–48.0%), and 59.2% (95% CI 47.6–70.8%), respectively in patients with postoperative chemotherapy while 38.1% (95% CI 24.8–51.4%) and 57.4% (95% CI 42.7–72.1%), respectively in patients without postoperative chemotherapy. Similarly, a meta-analysis of 14 randomized clinical data failed to identify significant benefit of postoperative chemotherapy in terms of OS( 18 ). Besides, the interim analysis of a European randomized phase 3 study manifested that full-dose anthracycline plus ifosfamide preoperative chemotherapy could improve the outcome of high-risk SS, with 2-year DFS of 71.7% and 64.4% in the control arm versus the experimental arm, respectively( 19 ), which was consistent with our result. Moreover, a pooled analysis of two large randomized trials (EORTC 62771 and 62931) manifested that no benefit of doxorubicin-based postoperative chemotherapy was achieved in the group of 108 SS patients( 20 ). Similar to other STS, tumor size has repeatedly been manifested to have prognostic value in SS patients( 1 ). In 2004, Naing et al. showed that tumor size predicted worse OS in a cohort of 1189 patients using registry data( 21 ). In our research, we also demonstrated that tumor size was an independent factor for both OS and TTR, which was the same as previous literatures. In addition, we identify age as an independent predictor of worse TTR. Although p value of age did not reach statistical significance for OS, it was very close to 0.05 so we thought it was still of vital importance to OS. Vlenterie et al. also showed that the outcomes of SS patients significantly decreased with age regardless of primary tumor site, size, and treatment( 22 ). Besides, necrosis was an essential factor in predicting worse OS. There are several limitations in our study. Firstly, it was difficult for us to enlarge our sample volume to add a validation cohort with which we could verify the accuracy and practicability of our conclusion as a result of the low morbidity of SS. Thus, prospective studies were warranted. Secondly, our level of evidence was inferior to prospective studies since it was a retrospective study and we had a few biases such as selection and data missing bias, which might have an impact on our conclusions. Thirdly, our study was single-institutional. Therefore, we are willing to collaborate with other sarcoma centers to further validate the accuracy and practicability of our results. Conclusion In summary, we analyzed a relatively large population database in our single cancer center to determine important clinicopathologic characteristics and the role of perioperative chemotherapy in high-grade SS patients. Notably, we did not find a significant contribution of postoperative chemotherapy in high-grade SS patients. However, there is a trend towards better OS and TTR in patients receiving preoperative chemotherapy, suggesting that chemotherapy should be performed ahead of surgery, that is in the presence of tumors, rather than after tumor resections for high-grade SS patients. Besides, age and tumor size were independent factors for TTR while tumor size and necrosis were independent predictors for worse OS. Abbreviations CIs confidence intervals DFS disease-free survival DSS disease-specific survival FNCLCC French Federation Nationale des Centres de Lutte Cotre le Caner IA anthracycline and ifosfamide OS overall survival SS synovial sarcoma STS soft tissue sarcoma TTR time to recurrence Declarations Ethics approval and consent to participate The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Research Ethics Committee of Shanghai Cancer Center (050432-4-2108). Informed consent was obtained from all subjects and/or their legal guardian(s). Consent for publication Not applicable. Availability of data and materials The datasets generated and analysed during the current study are not publicly available due privacy but are available from the corresponding author on reasonable request. Competing interests The authors declare that they have no competing interests. Funding This work was supported by National Natural Science Foundation of China (81701937, 81672851 and 81872179) and Shanghai Municipal Health Commission (20194Y0242). Authors' contributions Wangjun Yan and Yangbai Sun put forward the problem. Qiaowei Lin, Zhengwang Sun and Chunmeng Wang designed the whole process. Lin Yu and Qifeng Wang diagnosed SS in our patient cohorts as well as providing more detailed pathologic information. Qiaowei Lin and Peihang Xu collected the clinical information. Qiaowei Lin analyzed the data and wrote this article. All authors read and approved the final manuscript. Acknowledgements We thank Lin Yu and Qifeng Wang for their help in diagnosing synovial sarcoma in pathology as well as providing detailed pathological information. References Gazendam AM, Popovic S, Munir S, Parasu N, Wilson D, Ghert M. Synovial Sarcoma: A Clinical Review. Curr Oncol. 2021;28(3):1909-20. Aytekin MN, Öztürk R, Amer K, Yapar A. Epidemiology, incidence, and survival of synovial sarcoma subtypes: SEER database analysis. J Orthop Surg (Hong Kong). 2020;28(2):2309499020936009. Kampe CE, Rosen G, Eilber F, Eckardt J, Lowenbraun S, Foster J, et al. Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localized disease. Cancer. 1993;72(7):2161-9. Sultan I, Rodriguez-Galindo C, Saab R, Yasir S, Casanova M, Ferrari A. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer. 2009;115(15):3537-47. Smolle MA, Parry M, Jeys L, Abudu S, Grimer R. Synovial sarcoma: Do children do better? Eur J Surg Oncol. 2019;45(2):254-60. Wu Y, Bi W, Han G, Jia J, Xu M. Influence of neoadjuvant chemotherapy on prognosis of patients with synovial sarcoma. World J Surg Oncol. 2017;15(1):101. Nielsen TO, Poulin NM, Ladanyi M. Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy. Cancer Discov. 2015;5(2):124-34. Leyvraz S. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2007;18 Suppl 2:ii74-6. Verweij J, Seynaeve C. The reason for confining the use of adjuvant chemotherapy in soft tissue sarcoma to the investigational setting. Semin Radiat Oncol. 1999;9(4):352-9. Eilber FC, Brennan MF, Eilber FR, Eckardt JJ, Grobmyer SR, Riedel E, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg. 2007;246(1):105-13. Stacchiotti S, Van Tine BA. Synovial Sarcoma: Current Concepts and Future Perspectives. J Clin Oncol. 2018;36(2):180-7. Canter RJ, Qin LX, Maki RG, Brennan MF, Ladanyi M, Singer S. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res. 2008;14(24):8191-7. Vlenterie M, Litière S, Rizzo E, Marréaud S, Judson I, Gelderblom H, et al. Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. Eur J Cancer. 2016;58:62-72. Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer. 2010;46(1):72-83. Spurrell EL, Fisher C, Thomas JM, Judson IR. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol. 2005;16(3):437-44. Noujaim J, Constantinidou A, Messiou C, Thway K, Miah A, Benson C, et al. Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. Am J Clin Oncol. 2018;41(2):147-51. Xu G, Aiba H, Yamamoto N, Hayashi K, Takeuchi A, Miwa S, et al. Efficacy of perioperative chemotherapy for synovial sarcoma: a retrospective analysis of a Nationwide database in Japan. BMC Cancer. 2021;21(1):773. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350(9092):1647-54. Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18(6):812-22. Le Cesne A, Ouali M, Leahy MG, Santoro A, Hoekstra HJ, Hohenberger P, et al. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol. 2014;25(12):2425-32. Naing KW, Monjazeb AM, Li CS, Lee LY, Yang A, Borys D, et al. Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma: A SEER analysis. J Surg Oncol. 2015;111(2):158-64. Vlenterie M, Ho VK, Kaal SE, Vlenterie R, Haas R, van der Graaf WT. Age as an independent prognostic factor for survival of localised synovial sarcoma patients. Br J Cancer. 2015;113(11):1602-6. Tables Table 1. Clinical characteristics of synovial sarcoma patients (n=143). Variables No. (%) Gender Male 75（52%） Female 68（48%） Age (years) < 30 58（41%） ≥ 30 85（59%） Site Extremities and Trunks 130（91%） Abdomen and others 13（9%） Tumor size (cm) < 5 55（38%） ≥ 5 88（62%） Histology type Monophasic type 96（67%） Biphasic type 37（26%） Poorly differentiated type 10（7%） Necrosis Positive 58（41%） Negative 85（59%） Vessels Positive 16（11%） Negative 127（89%） Ki-67 < 50% 69（48%） ≥ 50% 74（52%） Invasive depth Superficial 12（8%） Muscle 115（81%） Visceral 16（11%） Preoperative chemotherapy Yes 17（12%） No 126（88%） Postoperative chemotherapy Yes 88（62%） No 55（38%） Recurrence Yes 84（59%） No 59（41%） Death Yes 52（36%） No 91（64%） Abbreviation: FNCLCC: French Federation Natinale des centres de Lutte Cotre le Cancer Table 2. The correlation between preoperative chemotherapy and clinicopathological features in the whole series (n=143). Variables Preoperative chemotherapy P * Yes No Gender Male 10 65 Female 7 61 0.6148 Age (years) < 30 8 50 ≥ 30 9 76 0.6050 Site Extremities and Trunks 15 115 Abdomen and others 2 11 0.6542 Tumor size (cm) < 5 7 48 ≥ 5 10 78 0.7969 Histology type Monophasic type 12 84 Biphasic type 3 34 Poorly differentiated type 2 8 0.5579 Necrosis Positive 8 50 Negative 9 76 0.6050 Vessels Positive 0 16 Negative 17 110 0.2176 Ki-67 < 50% 10 59 ≥ 50% 7 67 0.4410 Invasive depth Superficial 2 10 Muscle 13 102 Visceral 2 14 0.3047 Postperative chemotherapy Yes 13 75 No 4 51 0.2877 Recurrence Yes 8 76 No 9 50 0.3081 Death Yes 2 50 No 15 76 0.0375 Abbreviation: FNCLCC: French Federation Natinale des centres de Lutte Cotre le Cancer; *Pearson chi-square tests or Fisher’s exact tests for all the other analysis. Table 3. The correlation between postoperative chemotherapy and clinicopathological features in the whole series (n=143). Variables Postoperative chemotherapy P * Yes No Gender Male 43 32 Female 45 23 0.3053 Age (years) < 30 40 18 ≥ 30 48 37 0.1621 Site Extremities and Trunks 83 47 Abdomen and others 5 8 0.1319 Tumor size (cm) 0.9999 Vessels Positive 13 3 Negative 75 52 0.1058 Ki-67 < 50% 41 28 ≥ 50% 47 27 0.7310 Invasive depth Superficial 7 5 Muscle 70 45 Visceral 11 5 0.8084 Preoperative chemotherapy Yes 13 4 No 75 51 0.2877 Recurrence Yes 51 33 No 37 22 0.8624 Death Yes 31 21 No 57 34 0.7248 Abbreviation: FNCLCC: French Federation Natinale des centres de Lutte Cotre le Cancer; *Pearson chi-square tests or Fisher’s exact tests for all the other analysis. Table 4. Univariate and multivariate analyses of clinicopathological features and overall survival in synovial sarcoma patients. Variable Univariate analysis Multivariate analysis HR 95%CI P HR 95%CI P Gender Male vs. Female 0.894 0.680-1.176 0.425 Age (years) < 30 vs. ≥ 30 2.046 1.122-3.731 0.020 1.833 0.980-3.432 0.058 Site Extremities and Trunks vs. Abdomen and others 2.693 1.311-5.534 0.007 1.648 0.741-3.668 0.221 Tumor size (cm) <5 vs. ≥5 3.004 1.506-5.991 0.002 2.194 1.078-4.465 0.030 Histology type Monophasic type vs. Biphasic type 1.101 0.337-3.596 0.874 Monophasic type vs. Poorly differentiated type 1.736 0.508-5.938 0.379 Necrosis Positive vs. Negative 3.174 1.801-5.592 0.000 2.204 1.214-4.003 0.009 Vessels Positive vs. Negative 2.276 1.168-4.435 0.016 1.723 0.851-3.489 0.131 Ki-67 < 50% vs. ≥ 50% 1.894 1.060-3.382 0.031 1.460 0.798-2.671 0.219 Invasive depth Superficial vs. Muscle 0.873 0.285-2.672 0.812 Superficial vs. Visceral 0.763 0.356-1.633 0.486 Preoperative chemotherapy Yes vs. No 0.423 0.103-1.741 0.234 Postoperative chemotherapy Yes vs. No 1.032 0.593-1.796 0.912 Abbreviation: FNCLCC: French Federation Natinale des centres de Lutte Cotre le Cancer; Cox regression analyzes were done for all the above data. Table 5. Univariate and multivariate analyses of clinicopathological features and time to recurrence in synovial sarcoma patients. Variable Univariate analysis Multivariate analysis HR 95%CI P HR 95%CI P Gender Male vs. Female 1.010 0.658-1.551 0.963 Age (years) < 30 vs. ≥ 30 2.205 1.372-3.545 0.001 2.028 1.247-3.298 0.004 Site Extremities and Trunks vs. Abdomen and others 2.436 1.289-4.603 0.006 1.676 0.863-3.252 0.127 Tumor size (cm) <5 vs. ≥5 2.144 1.326-3.467 0.002 2.011 1.231-3.286 0.005 Histology type Monophasic type vs. Biphasic type 1.259 0.504-3.145 0.622 Monophasic type vs. Poorly differentiated type 1.334 0.506-3.515 0.560 Necrosis Positive vs. Negative 1.791 1.165-2.755 0.008 1.296 0.829-2.026 0.255 Vessels Positive vs. Negative 1.684 0.912-3.109 0.096 Ki-67 < 50% vs. ≥ 50% 1.724 1.110-2.680 0.015 1.518 0.967-2.383 0.070 Invasive depth Superficial vs. Muscle 0.651 0.256-1.656 0.368 Superficial vs. Visceral 0.616 0.332-1.141 0.123 Preoperative chemotherapy Yes vs. No 0.786 0.379-1.630 0.517 Postoperative chemotherapy Yes vs. No 0.955 0.616-1.480 0.836 Abbreviation: FNCLCC: French Federation Natinale des centres de Lutte Cotre le Cancer; Cox regression analyzes were done for all the above data. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-2054776","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":137428349,"identity":"6db3631f-2f15-4d5a-b3a5-1adcf7189e75","order_by":0,"name":"Qiaowei Lin","email":"","orcid":"","institution":"Fudan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Qiaowei","middleName":"","lastName":"Lin","suffix":""},{"id":137428350,"identity":"a2ffff23-2583-4b7b-8978-22de35bdc771","order_by":1,"name":"Peihang Xu","email":"","orcid":"","institution":"Fudan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Peihang","middleName":"","lastName":"Xu","suffix":""},{"id":137428351,"identity":"4c57a867-6dc9-4447-a96c-44538079ef10","order_by":2,"name":"Zhengwang Sun","email":"","orcid":"","institution":"Fudan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Zhengwang","middleName":"","lastName":"Sun","suffix":""},{"id":137428352,"identity":"3c9fe84e-a517-4b41-b32b-8c2fd1d8b160","order_by":3,"name":"Lin Yu","email":"","orcid":"","institution":"Fudan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Lin","middleName":"","lastName":"Yu","suffix":""},{"id":137428353,"identity":"cd69d675-b71c-49e5-9be0-59b93a34ffd4","order_by":4,"name":"Chunmeng Wang","email":"","orcid":"","institution":"Fudan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Chunmeng","middleName":"","lastName":"Wang","suffix":""},{"id":137428354,"identity":"90a5a387-e3eb-4469-b4dc-f5470d224685","order_by":5,"name":"Qifeng Wang","email":"","orcid":"","institution":"Fudan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Qifeng","middleName":"","lastName":"Wang","suffix":""},{"id":137428356,"identity":"44eb0900-5d04-4661-8d59-7d06c2f9675b","order_by":6,"name":"Yangbai Sun","email":"","orcid":"","institution":"Fudan University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Yangbai","middleName":"","lastName":"Sun","suffix":""},{"id":137428359,"identity":"40ed2d79-1da0-465c-b14a-552dd232f787","order_by":7,"name":"Wangjun Yan","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA1klEQVRIiWNgGAWjYLACiQo5BoYDIBYb0VrOGJOqhbGNFC0Gx88ek7CcZ5DYd/zsAYYPZYcZ+Gc3ENByJi9NQnKbQeLMM3kJjDPOHWaQuHOAgJYDOWY3JLf9SdxwIMeAmbftMIOBRAIBLeffALXMMUjccP6NAfNforTcANnSANRyA2gLIzFaJG+8Mf8hcczAeOaNNwYHe86l80jcIKCF73yOsbFEjYFs3/kcwwc/yqzl+GcQ0KJwgIGBWQLKAbIZePCrBwL5BmBMfiCobBSMglEwCkY0AAC3ckjk+G26ygAAAABJRU5ErkJggg==","orcid":"","institution":"Fudan University","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Wangjun","middleName":"","lastName":"Yan","suffix":""}],"badges":[],"createdAt":"2022-09-12 00:59:20","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-2054776/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-2054776/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":26737907,"identity":"3b2b72bc-63a5-4fff-984d-d0dcc079e054","added_by":"auto","created_at":"2022-09-20 23:18:15","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":409188,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003ePrognostic significance of perioperative chemotherapy in SS patients (n=143).\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA. Kaplan-Meier analysis of time to recurrence (TTR) stratified by preoperative chemotherapy.\u003c/p\u003e\n\u003cp\u003eB. Kaplan-Meier analysis of overall survival (OS) stratified by preoperative chemotherapy.\u003c/p\u003e\n\u003cp\u003eC. Kaplan-Meier analysis of TTR stratified by postoperative chemotherapy.\u003c/p\u003e\n\u003cp\u003eD. Kaplan-Meier analysis of OS stratified by postoperative chemotherapy.\u003c/p\u003e","description":"","filename":"Figure1a.png","url":"https://assets-eu.researchsquare.com/files/rs-2054776/v1/a1255d71a8453d8efa728fe4.png"},{"id":27063841,"identity":"7815eb77-8482-4253-b282-89b6f1bad4c8","added_by":"auto","created_at":"2022-09-28 05:29:31","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":828708,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-2054776/v1/e5f29b82-0b7a-43b3-bf8a-7a08cbcb767b.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Role of perioperative chemotherapy for high-grade synovial sarcoma: a retrospective study of a single Asian cohort in China","fulltext":[{"header":"Background","content":"\u003cp\u003eSynovial sarcoma (SS), which is an aggressive soft tissue sarcoma (STS), accounts for 5%-10% of all STS(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e). It prefers to occur at a younger mean age of onset, especially adolescents and young adults, which is unique from other STS(\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e). Pathologically, SS can be divided into three histologic subtypes: monophasic type, biphasic type, and poorly differentiated type. Genetically, it possesses a constant chromosomal translocation between chromosomes 18 and X in greater than 95% cases, leading to the expression of different SS18: SSX oncogenic fusion proteins(\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e). Despite its name, SS is not derived from synovial tissues. It can occur anywhere in the body, with a predilection for the extremities of young adults, frequently seen in soft tissues around the joint(\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e). Generally, this high-grade sarcoma is characterized by high potentials of developing recurrence and metastasis, 70% to the lung and 10\u0026thinsp;~\u0026thinsp;20% to the bone(\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e). 5-year survival rate for children and adolescents were reported to be 83% compared to 62% in adults by utilizing registry data(\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e). Similarly, Smolle et al. demonstrated an 89% 5-year cancer specific survival rate in children compared to 75% in adults(\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eWide surgical resection, complemented by radiotherapy in cases of large tumors or invaded margins, remains the mainstay treatment options for localized SS(\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e). Similar to other high-grade STS subtypes, in order to decrease the risk of local recurrence and distant metastasis due to the existence of subclinical micrometastasis, perioperative chemotherapy is commonly considered as a rational approach for high-grade SS(\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e). However, though SS is considered a relatively chemosensitive tumor compared with other STS, there are only scarce and conflicting researches about the benefit of perioperative chemotherapy in patients with high-grade SS(\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e). In 2007, Eilber et al. demonstrated that ifosfamide-based chemotherapy was associated with an improved disease-specific survival (DSS) in adult patients with primary, extremity, high-risk SS(\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e). However, contrary to this, the French Sarcoma Group observed no overall survival (OS) benefit with perioperative chemotherapy in adult SS patients(\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e). Nevertheless, this study included patients carrying low-risk tumor characteristics in which chemotherapy is unlikely to be of benefit. Therefore, our research was conducted to clarify the role of perioperative chemotherapy in high-grade SS patients and to identify independent prognostic factors for SS. To this aim, 143 patients with resectable high-grade SS in our single cancer center were retrospectively reviewed and enrolled in.\u003c/p\u003e"},{"header":"Materials And Methods","content":"\u003cp\u003e\u003cstrong\u003ePatients\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eFrom 2006 to 2020, 143 patients who underwent curative resections and diagnosed as G3 SS in our cancer center were retrospectively reviewed and enrolled in this study. The inclusion criteria were as follows: 1) Locally resectable tumors; 2) R0 resections; 2) No metastatic tumors of lung; 3) Histologically diagnosed as SS; 4) No secondary tumor; 5) French Federation Nationale des Centres de Lutte Cotre le Caner (FNCLCC) classification of grade 3; 6) Complete clinicopathologic information and follow-up information. Informed signed written consents were obtained from patients and/or their legal guardians. Ethical approval was obtained from the Research Ethics Committee of Shanghai Cancer Center (050432-4-2108).\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePathological examinations\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTwo independent pathologists (Lin Yu and Qifeng Wang), who were specialized in diagnosing STS in our cancer center, reviewed the pathological slides through microscope and confirmed the pathological diagnosis of SS. The following pathological characteristics, such as tumor location, tumor size, histologic type, incisal margin, necrosis, vessel infiltration, invasive depth, Ki-67 proliferative index, SS18 conditions, and FNCLCC classification were recorded for further analysis.\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFollow-up data\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe achieved our follow-up data through telephones and electronic medical records of our center. We ended our followed up in December 2021. Two endpoints were set in our study, that were OS, which was defined as the interval from the date of surgery to death from any cause or last follow-up time, and time to recurrence (TTR), which was calculated from the date of surgery to the date of recurrence or last follow-up time.\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe administration of chemotherapy\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe patients with perioperative chemotherapy received an anthracycline- and ifosfamide-containing (IA) regimen: ifosfamide 1.8g/m\u003csup\u003e2\u003c/sup\u003e/d from day 1 to day 5 plus doxorubicin 60mg/m\u003csup\u003e2\u003c/sup\u003e/d short infusion on day 1 every 21 days. The patients with preoperative chemotherapy received chemotherapy for about 2 to 3 treatment courses before surgery, approximately 0 or 5 to 6 treatment courses after surgery. As for the patients with postoperative chemotherapy, approximately 1 month after surgery, we performed IA regimen on them, who received about 5 to 6 treatment courses. \u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eStatistical analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eOS and TTR were assessed by Kaplan‑Meier curves with 95% confidence intervals (CIs) for SS patients underwent curative surgeries. Differences between OS and TTR were compared using the log‑rank test. Univariate and multivariate analyses were carried out by Cox regression analysis. Variables significantly associated with OS or TTR in the univariate analysis were incorporated into multivariate analyses to identify independent prognostic factors. Pearson chi-square test was used to analyze the relationship between patients with chemotherapy and without chemotherapy concerning clinicopathologic characteristics and Fisher\u0026rsquo;s exact test was used when necessary. All statistical analyses were performed using IBM SPSS Statistics 23 (SPSS Inc., Armonk, NY, USA). \u003cem\u003ep\u003c/em\u003e-value \u0026lt;0.05 was considered statistically significant.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003e\u003cstrong\u003ePatient characteristics\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eFrom 2006 to 2020, 143 patients who underwent curative surgery and been diagnosed as high-grade SS in Shanghai Cancer Center, Fudan University were included in our analysis. Detailed clinical characteristics were shown in \u003cstrong\u003eTable 1\u003c/strong\u003e. There were 75 males and 68 females with an average age of 36.7 years (range 15-71 years) in this study. 85 patients were older than 30 years old at the time of initial diagnosis. The tumor sites of involvement were mostly in the extremities and trunks (n=130). Overall, the average size of the tumors was 6.8cm (range 1-23cm). 88 patients had tumors larger than 5cm. The distributions of the histology type were as follows: monophasic type 96 cases, biphasic type 37 cases, and poorly differentiated type 10 cases. Necrosis and vessel infiltration could be detected in 58 and 16 patients, respectively. With regard to invasive depth, the majority of tumors infiltrated to muscles (n=115), followed by viscera (n=16) and superficial tissues (n=11). At the end of follow-up period, 84 patients suffered from postoperative local recurrence or distant metastasis while 52 patients died from SS or other reasons.\u003c/p\u003e\n\u003cp\u003eAmong 143 patients, pre- and post-operative chemotherapy were delivered in 17 cases (12%) and 88 cases (62%), respectively (\u003cstrong\u003eTable 1\u003c/strong\u003e). 13 patients received both pre- and post-operative chemotherapy. Clinicopathologic characteristics were not significantly different between patients with chemotherapy and those without (\u003cstrong\u003eTable 2\u003c/strong\u003e and \u003cstrong\u003eTable 3\u003c/strong\u003e). \u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKaplan-Meier curves of TTR and OS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eKaplan-Meier curves were performed to evaluate the prognostic values of perioperative chemotherapy in high-grade SS patients. However, we did not see any significant differences in OS or TTR with regard to the status of perioperative chemotherapy (Figure 1). Although preoperative chemotherapy did not reach statistical significance, there was a trend that patients with preoperative chemotherapy had better OS and TTR than those without in the long term (Figure 1A and 1B). The 3-year and 5-year TTR rates of the patients receiving preoperative chemotherapy were 49.9% (95% CI 24.6% to 75.2%) and 49.9% (95% CI 24.6% to 75.2%), respectively, and that of the patients receiving non-preoperative chemotherapy were 45.3% (95% CI 36.5% to 54.1%) and 36.2% (95% CI 27.2% to 45.2%), respectively. The corresponding OS probabilities at 3-year and 5-year were 84.4% (95% CI 64.0% to 104.8%), 84.4% (95% CI 64.0% to 104.8%), respectively in the preoperative chemotherapy group while 66.8% (95% CI 58.2% to 75.4%), 56.6% (95% CI 47.0% to 66.2%), respectively in the non-preoperative chemotherapy group. As for postoperative chemotherapy, we observed that the 3-year and 5-year TTR rates of the patients with it were 47.6% (95% CI 36.8% to 58.3%) and 36.6% (95% CI 25.2% to 48.0%), respectively, and that of the patients without it were 43.2% (95% CI 30.1% to 56.3%) and 38.1% (95% CI 24.8% to 51.4%), respectively. The corresponding OS probabilities at 3-year and 5-year were 66.3% (95% CI 55.7% to 76.9%), 59.2% (95% CI 47.6% to 70.8%), respectively in the postoperative chemotherapy group while 70.7% (95% CI 58.2% to 83.2%), 57.4% (95% CI 42.7% to 72.1%), respectively in the non-postoperative chemotherapy group.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eUnivariate and multivariate analyses of SS patients\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eUnivariate and multivariate analyses were performed to explore the independent prognostic factors for OS and TTR in SS. In the univariate analysis, age \u0026ge; 30 years, deep locations, tumor size \u0026ge; 5cm, necrosis and Ki-67 proliferative index \u0026ge; 50% were adverse prognostic factors for both OS (\u003cstrong\u003eTable 4\u003c/strong\u003e) and TTR (\u003cstrong\u003eTable 5\u003c/strong\u003e). Besides, patients without vessel infiltration had a favorable outcome for OS (\u003cstrong\u003eTable 4\u003c/strong\u003e). Further multivariate analyses identified tumor size (HR: 2.194,\u003cem\u003e p\u003c/em\u003e = 0.030) and necrosis (HR: 2.204,\u003cem\u003e p\u003c/em\u003e = 0.009) as independent prognostic factors for OS (\u003cstrong\u003eTable 4\u003c/strong\u003e). Meanwhile, age (HR: 2.028,\u003cem\u003e p\u003c/em\u003e = 0.004) and tumor size (HR: 2.011,\u003cem\u003e p\u003c/em\u003e = 0.005) were highly significant independent predictors of worse TTR (\u003cstrong\u003eTable 5\u003c/strong\u003e).\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eGenerally, SS is considered a high-grade sarcoma, marked by a poor prognosis, with an expected 5-year OS in adult patients ranging from 50\u0026ndash;60% and a 5-year metastatic disease-free survival (DFS) ranging from 40\u0026ndash;60%(\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e). There has been a trend for improved survival over time with early cohorts from the 1960s quoting a 25\u0026ndash;51% 5-year OS rate(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e). However, due to its rarity, the knowledge about SS is usually restricted in small single-center analysis, resulting in uncertainty about the optimal treatments for them. Till today, though SS is thought to be a kind of chemosensitive sarcoma, it remains challenging to accurately assess the function of perioperative chemotherapy in high-grade SS patients(\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e). To elucidate the role of perioperative chemotherapy and to clarify important clinicopathological characteristics in high-grade SS, 143 SS patients underwent curative surgeries in our cancer center were retrospectively reviewed and enrolled in this research. Among them, preoperative chemotherapy was delivered in 17 cases while postoperative chemotherapy was performed in 88 cases.\u003c/p\u003e \u003cp\u003eAnthracycline-based chemotherapy is the conventional first line for advanced STS. As the antitumor efficacy of ifosfamide is well known in SS, the regimen of anthracycline plus ifosfamide is commonly suggested for SS patients(\u003cspan additionalcitationids=\"CR15\" citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e). Conclusions concerning the function of perioperative chemotherapy vary greatly, possibly because it is difficult to conduct a prospective study on the effect of perioperative chemotherapy, specifically for this tumor type(\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e). In 2007, after retrospectively analyzing 101 adult SS patients, researchers from Memorial Sloan Kettering Cancer Center concluded that ifosfamide-based chemotherapy improved DSS in adult patients with high-risk, primary, extremity, SS(\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e). The 4-year DSS for patients treated with ifosfamide and doxorubicin was 88%, compared with 67% for patients in the control arm. However, by contrast, we did not see significant differences in OS or TTR between patients with perioperative chemotherapy and patients without. There was a trend towards better OS and TTR for patients receiving preoperative chemotherapy in the long term. This phenomenon might partly be explained by the sample size as we only had 17 patients receiving preoperative chemotherapy, which was hard for us to draw a definitive conclusion. The 5-year TTR or OS rates of the patients receiving preoperative chemotherapy were 49.9% (95% CI 24.6\u0026ndash;75.2%), and 84.4% (95% CI 64.0\u0026ndash;104.8%), respectively, and that of the patients receiving non-preoperative chemotherapy were 36.2% (95% CI 27.2\u0026ndash;45.2%), and 56.6% (95% CI 47.0\u0026ndash;66.2%), respectively. The corresponding TTR or OS probabilities at 5-year were 36.6% (95% CI 25.2\u0026ndash;48.0%), and 59.2% (95% CI 47.6\u0026ndash;70.8%), respectively in patients with postoperative chemotherapy while 38.1% (95% CI 24.8\u0026ndash;51.4%) and 57.4% (95% CI 42.7\u0026ndash;72.1%), respectively in patients without postoperative chemotherapy. Similarly, a meta-analysis of 14 randomized clinical data failed to identify significant benefit of postoperative chemotherapy in terms of OS(\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e). Besides, the interim analysis of a European randomized phase 3 study manifested that full-dose anthracycline plus ifosfamide preoperative chemotherapy could improve the outcome of high-risk SS, with 2-year DFS of 71.7% and 64.4% in the control arm versus the experimental arm, respectively(\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e), which was consistent with our result. Moreover, a pooled analysis of two large randomized trials (EORTC 62771 and 62931) manifested that no benefit of doxorubicin-based postoperative chemotherapy was achieved in the group of 108 SS patients(\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eSimilar to other STS, tumor size has repeatedly been manifested to have prognostic value in SS patients(\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e). In 2004, Naing et al. showed that tumor size predicted worse OS in a cohort of 1189 patients using registry data(\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e). In our research, we also demonstrated that tumor size was an independent factor for both OS and TTR, which was the same as previous literatures. In addition, we identify age as an independent predictor of worse TTR. Although \u003cem\u003ep\u003c/em\u003e value of age did not reach statistical significance for OS, it was very close to 0.05 so we thought it was still of vital importance to OS. Vlenterie et al. also showed that the outcomes of SS patients significantly decreased with age regardless of primary tumor site, size, and treatment(\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e). Besides, necrosis was an essential factor in predicting worse OS.\u003c/p\u003e \u003cp\u003eThere are several limitations in our study. Firstly, it was difficult for us to enlarge our sample volume to add a validation cohort with which we could verify the accuracy and practicability of our conclusion as a result of the low morbidity of SS. Thus, prospective studies were warranted. Secondly, our level of evidence was inferior to prospective studies since it was a retrospective study and we had a few biases such as selection and data missing bias, which might have an impact on our conclusions. Thirdly, our study was single-institutional. Therefore, we are willing to collaborate with other sarcoma centers to further validate the accuracy and practicability of our results.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003e In summary, we analyzed a relatively large population database in our single cancer center to determine important clinicopathologic characteristics and the role of perioperative chemotherapy in high-grade SS patients. Notably, we did not find a significant contribution of postoperative chemotherapy in high-grade SS patients. However, there is a trend towards better OS and TTR in patients receiving preoperative chemotherapy, suggesting that chemotherapy should be performed ahead of surgery, that is in the presence of tumors, rather than after tumor resections for high-grade SS patients. Besides, age and tumor size were independent factors for TTR while tumor size and necrosis were independent predictors for worse OS.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cdiv class=\"DefinitionList\"\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eCIs\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003econfidence intervals\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eDFS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003edisease-free survival\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eDSS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003edisease-specific survival\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eFNCLCC\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eFrench Federation Nationale des Centres de Lutte Cotre le Caner\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eIA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eanthracycline and ifosfamide\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eOS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eoverall survival\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eSS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003esynovial sarcoma\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eSTS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003esoft tissue sarcoma\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eTTR\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003etime to recurrence\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Research Ethics Committee of Shanghai Cancer Center (050432-4-2108). Informed consent was obtained from all subjects and/or their legal guardian(s).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets generated and analysed during the current study are not publicly available due privacy but are available from the corresponding author on reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was supported by National Natural Science Foundation of China (81701937, 81672851 and 81872179) and Shanghai Municipal Health Commission (20194Y0242).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWangjun Yan and Yangbai Sun put forward the problem. Qiaowei Lin, Zhengwang Sun and Chunmeng Wang designed the whole process. Lin Yu and Qifeng Wang diagnosed SS in our patient cohorts as well as providing more detailed pathologic information. Qiaowei Lin and Peihang Xu collected the clinical information. Qiaowei Lin analyzed the data and wrote this article.\u003c/p\u003e\n\u003cp\u003eAll authors read and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe thank Lin Yu and Qifeng Wang for their help in diagnosing synovial sarcoma in pathology as well as providing detailed pathological information.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eGazendam AM, Popovic S, Munir S, Parasu N, Wilson D, Ghert M. Synovial Sarcoma: A Clinical Review. Curr Oncol. 2021;28(3):1909-20.\u003c/li\u003e\n\u003cli\u003eAytekin MN, \u0026Ouml;zt\u0026uuml;rk R, Amer K, Yapar A. Epidemiology, incidence, and survival of synovial sarcoma subtypes: SEER database analysis. J Orthop Surg (Hong Kong). 2020;28(2):2309499020936009.\u003c/li\u003e\n\u003cli\u003eKampe CE, Rosen G, Eilber F, Eckardt J, Lowenbraun S, Foster J, et al. Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localized disease. Cancer. 1993;72(7):2161-9.\u003c/li\u003e\n\u003cli\u003eSultan I, Rodriguez-Galindo C, Saab R, Yasir S, Casanova M, Ferrari A. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer. 2009;115(15):3537-47.\u003c/li\u003e\n\u003cli\u003eSmolle MA, Parry M, Jeys L, Abudu S, Grimer R. Synovial sarcoma: Do children do better? Eur J Surg Oncol. 2019;45(2):254-60.\u003c/li\u003e\n\u003cli\u003eWu Y, Bi W, Han G, Jia J, Xu M. Influence of neoadjuvant chemotherapy on prognosis of patients with synovial sarcoma. World J Surg Oncol. 2017;15(1):101.\u003c/li\u003e\n\u003cli\u003eNielsen TO, Poulin NM, Ladanyi M. Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy. Cancer Discov. 2015;5(2):124-34.\u003c/li\u003e\n\u003cli\u003eLeyvraz S. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2007;18 Suppl 2:ii74-6.\u003c/li\u003e\n\u003cli\u003eVerweij J, Seynaeve C. The reason for confining the use of adjuvant chemotherapy in soft tissue sarcoma to the investigational setting. Semin Radiat Oncol. 1999;9(4):352-9.\u003c/li\u003e\n\u003cli\u003eEilber FC, Brennan MF, Eilber FR, Eckardt JJ, Grobmyer SR, Riedel E, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg. 2007;246(1):105-13.\u003c/li\u003e\n\u003cli\u003eStacchiotti S, Van Tine BA. Synovial Sarcoma: Current Concepts and Future Perspectives. J Clin Oncol. 2018;36(2):180-7.\u003c/li\u003e\n\u003cli\u003eCanter RJ, Qin LX, Maki RG, Brennan MF, Ladanyi M, Singer S. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res. 2008;14(24):8191-7.\u003c/li\u003e\n\u003cli\u003eVlenterie M, Liti\u0026egrave;re S, Rizzo E, Marr\u0026eacute;aud S, Judson I, Gelderblom H, et al. Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. Eur J Cancer. 2016;58:62-72.\u003c/li\u003e\n\u003cli\u003eSleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer. 2010;46(1):72-83.\u003c/li\u003e\n\u003cli\u003eSpurrell EL, Fisher C, Thomas JM, Judson IR. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol. 2005;16(3):437-44.\u003c/li\u003e\n\u003cli\u003eNoujaim J, Constantinidou A, Messiou C, Thway K, Miah A, Benson C, et al. Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. Am J Clin Oncol. 2018;41(2):147-51.\u003c/li\u003e\n\u003cli\u003eXu G, Aiba H, Yamamoto N, Hayashi K, Takeuchi A, Miwa S, et al. Efficacy of perioperative chemotherapy for synovial sarcoma: a retrospective analysis of a Nationwide database in Japan. BMC Cancer. 2021;21(1):773.\u003c/li\u003e\n\u003cli\u003eAdjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350(9092):1647-54.\u003c/li\u003e\n\u003cli\u003eGronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18(6):812-22.\u003c/li\u003e\n\u003cli\u003eLe Cesne A, Ouali M, Leahy MG, Santoro A, Hoekstra HJ, Hohenberger P, et al. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol. 2014;25(12):2425-32.\u003c/li\u003e\n\u003cli\u003eNaing KW, Monjazeb AM, Li CS, Lee LY, Yang A, Borys D, et al. Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma: A SEER analysis. J Surg Oncol. 2015;111(2):158-64.\u003c/li\u003e\n\u003cli\u003eVlenterie M, Ho VK, Kaal SE, Vlenterie R, Haas R, van der Graaf WT. Age as an independent prognostic factor for survival of localised synovial sarcoma patients. Br J Cancer. 2015;113(11):1602-6.\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003e\u003cstrong\u003eTable 1. Clinical characteristics of synovial sarcoma patients (n=143).\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u003cstrong\u003eVariables\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e\u003cstrong\u003eNo. (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u003cstrong\u003eGender\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Male\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e75（52%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Female\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e68（48%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge (years)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026lt; 30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e58（41%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026ge; 30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e85（59%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u003cstrong\u003eSite\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Extremities and Trunks\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e130（91%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Abdomen and others\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e13（9%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u003cstrong\u003eTumor size (cm)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026lt; 5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e55（38%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026ge; 5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e88（62%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u003cstrong\u003eHistology type\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Monophasic type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e96（67%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Biphasic type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e37（26%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Poorly differentiated type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e10（7%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u003cstrong\u003eNecrosis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Positive\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e58（41%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Negative\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e85（59%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u003cstrong\u003eVessels\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Positive\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e16（11%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Negative\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e127（89%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u003cstrong\u003eKi-67\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026lt; 50%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e69（48%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026ge; 50%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e74（52%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u003cstrong\u003eInvasive depth\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Superficial\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e12（8%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Muscle\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e115（81%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Visceral\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e16（11%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u003cstrong\u003ePreoperative chemotherapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e17（12%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e126（88%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u003cstrong\u003ePostoperative chemotherapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e88（62%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e55（38%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u003cstrong\u003eRecurrence\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e84（59%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e59（41%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u003cstrong\u003eDeath\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e52（36%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 60.6811%;\" valign=\"top\" width=\"51.35623869801085%\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 39.3189%;\" valign=\"top\" width=\"33.273056057866185%\"\u003e\n \u003cp\u003e91（64%）\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eAbbreviation:\u003c/em\u003e\u003c/strong\u003e FNCLCC: French Federation Natinale des centres de Lutte Cotre le Cancer\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2. The correlation between preoperative chemotherapy and clinicopathological features in the whole series (n=143).\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"margin-right: calc(26%); width: 74%;\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eVariables\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width: 21.127%;\" valign=\"top\" width=\"42.67631103074141%\"\u003e\n \u003cp\u003e\u003cstrong\u003ePreoperative chemotherapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width: 38.623%;\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eP\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"47.88135593220339%\"\u003e\n \u003cp\u003e\u003cstrong\u003eYes\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" width=\"52.11864406779661%\"\u003e\n \u003cp\u003e\u003cstrong\u003eNo\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eGender\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Male\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e65\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Female\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e61\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.6148\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge (years)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026lt; 30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026ge; 30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e76\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.6050\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eSite\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Extremities and Trunks\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e115\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Abdomen and others\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.6542\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eTumor size (cm)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026lt; 5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e48\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026ge; 5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e78\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.7969\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eHistology type\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Monophasic type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e84\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Biphasic type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Poorly differentiated type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.5579\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eNecrosis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Positive\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Negative\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e76\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.6050\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eVessels\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Positive\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Negative\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e110\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.2176\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eKi-67\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026lt; 50%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e59\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026ge; 50%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e67\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.4410\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eInvasive depth\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Superficial\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Muscle\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e102\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Visceral\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.3047\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003ePostperative chemotherapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e51\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.2877\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eRecurrence\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e76\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.3081\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eDeath\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.5234%;\" valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 8.877%;\" valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e76\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 38.623%;\" valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.0375\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eAbbreviation:\u003c/em\u003e\u003c/strong\u003e FNCLCC: French Federation Natinale des centres de Lutte Cotre le Cancer;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e*Pearson chi-square tests or Fisher\u0026rsquo;s exact tests for all the other analysis.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 3. The correlation between postoperative chemotherapy and clinicopathological features in the whole series (n=143).\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eVariables\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" width=\"42.67631103074141%\"\u003e\n \u003cp\u003e\u003cstrong\u003ePostoperative chemotherapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eP\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"47.88135593220339%\"\u003e\n \u003cp\u003e\u003cstrong\u003eYes\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"52.11864406779661%\"\u003e\n \u003cp\u003e\u003cstrong\u003eNo\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eGender\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Male\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e43\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Female\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.3053\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge (years)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026lt; 30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e40\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026ge; 30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e48\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e37\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.1621\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eSite\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Extremities and Trunks\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e83\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Abdomen and others\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.1319\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eTumor size (cm)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026lt; 5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026ge; 5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e56\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.5967\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eHistology type\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Monophasic type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e63\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Biphasic type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Poorly differentiated type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.0519\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eNecrosis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Positive\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e22\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Negative\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e52\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026gt;0.9999\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eVessels\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Positive\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Negative\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e52\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.1058\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eKi-67\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026lt; 50%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026ge; 50%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.7310\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eInvasive depth\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Superficial\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Muscle\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e70\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Visceral\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.8084\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003ePreoperative chemotherapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e51\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.2877\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eRecurrence\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e51\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e37\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e22\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.8624\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u003cstrong\u003eDeath\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"41.04882459312839%\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"20.43399638336347%\"\u003e\n \u003cp\u003e57\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"22.24231464737794%\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"16.2748643761302%\"\u003e\n \u003cp\u003e0.7248\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eAbbreviation:\u003c/em\u003e\u003c/strong\u003e FNCLCC: French Federation Natinale des centres de Lutte Cotre le Cancer;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e*Pearson chi-square tests or Fisher\u0026rsquo;s exact tests for all the other analysis.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 4. Univariate and multivariate analyses of clinicopathological features and overall survival in synovial sarcoma patients.\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 32.1944%;\" valign=\"top\" width=\"36.734693877551024%\"\u003e\n \u003cp\u003e\u003cstrong\u003eVariable\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 43.8134%;\" valign=\"top\" width=\"31.632653061224488%\"\u003e\n \u003cp\u003e\u003cstrong\u003eUnivariate analysis\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 19.365%;\" valign=\"top\" width=\"30.612244897959183%\"\u003e\n \u003cp\u003e\u003cstrong\u003eMultivariate analysis\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"13.114754098360656%\"\u003e\n \u003cp\u003eHR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"22.950819672131146%\"\u003e\n \u003cp\u003e95%CI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"14.754098360655737%\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"11.475409836065573%\"\u003e\n \u003cp\u003eHR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"22.950819672131146%\"\u003e\n \u003cp\u003e95%CI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"13.114754098360656%\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eGender\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003eMale vs. Female\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e0.894\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.680-1.176\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e0.425\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge (years)\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026lt; 30 vs. \u0026ge; 30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e2.046\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e1.122-3.731\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.020\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e1.833\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.980-3.432\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e0.058\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eSite\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Extremities and Trunks vs. Abdomen and others\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e2.693\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e1.311-5.534\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.007\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e1.648\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.741-3.668\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e0.221\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eTumor size (cm)\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026lt;5 vs. \u0026ge;5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e3.004\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e1.506-5.991\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.002\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e2.194\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e1.078-4.465\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.030\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eHistology type\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Monophasic type vs. Biphasic type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e1.101\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.337-3.596\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e0.874\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Monophasic type vs. Poorly differentiated type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e1.736\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.508-5.938\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e0.379\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eNecrosis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Positive vs. Negative\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e3.174\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e1.801-5.592\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.000\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e2.204\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e1.214-4.003\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.009\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eVessels\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Positive vs. Negative\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e2.276\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e1.168-4.435\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.016\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e1.723\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.851-3.489\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e0.131\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eKi-67\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026lt; 50% vs. \u0026ge; 50%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e1.894\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e1.060-3.382\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.031\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e1.460\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.798-2.671\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e0.219\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eInvasive depth\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Superficial vs. Muscle\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e0.873\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.285-2.672\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e0.812\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Superficial vs. Visceral\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e0.763\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.356-1.633\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e0.486\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003ePreoperative chemotherapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes vs. No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e0.423\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.103-1.741\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e0.234\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003ePostoperative chemotherapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes vs. No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e1.032\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.593-1.796\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e0.912\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eAbbreviation:\u003c/em\u003e\u003c/strong\u003e FNCLCC: French Federation Natinale des centres de Lutte Cotre le Cancer;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eCox regression analyzes were done for all the above data.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 5. Univariate and multivariate analyses of clinicopathological features and time to recurrence in synovial sarcoma patients.\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 32.1944%;\" valign=\"top\" width=\"36.734693877551024%\"\u003e\n \u003cp\u003e\u003cstrong\u003eVariable\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 43.8134%;\" valign=\"top\" width=\"31.632653061224488%\"\u003e\n \u003cp\u003e\u003cstrong\u003eUnivariate analysis\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" style=\"width: 19.365%;\" valign=\"top\" width=\"30.612244897959183%\"\u003e\n \u003cp\u003e\u003cstrong\u003eMultivariate analysis\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"13.114754098360656%\"\u003e\n \u003cp\u003eHR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"22.950819672131146%\"\u003e\n \u003cp\u003e95%CI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"14.754098360655737%\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"11.475409836065573%\"\u003e\n \u003cp\u003eHR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"22.950819672131146%\"\u003e\n \u003cp\u003e95%CI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"13.114754098360656%\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eGender\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003eMale vs. Female\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e1.010\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.658-1.551\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e0.963\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge (years)\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026lt; 30 vs. \u0026ge; 30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e2.205\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e1.372-3.545\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e2.028\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e1.247-3.298\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.004\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eSite\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Extremities and Trunks vs. Abdomen and others\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e2.436\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e1.289-4.603\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.006\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e1.676\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.863-3.252\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e0.127\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eTumor size (cm)\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026lt;5 vs. \u0026ge;5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e2.144\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e1.326-3.467\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.002\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e2.011\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e1.231-3.286\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.005\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eHistology type\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Monophasic type vs. Biphasic type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e1.259\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.504-3.145\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e0.622\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Monophasic type vs. Poorly differentiated type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e1.334\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.506-3.515\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e0.560\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eNecrosis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Positive vs. Negative\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e1.791\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e1.165-2.755\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.008\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e1.296\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.829-2.026\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e0.255\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eVessels\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Positive vs. Negative\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e1.684\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.912-3.109\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e0.096\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eKi-67\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026lt; 50% vs. \u0026ge; 50%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e1.724\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e1.110-2.680\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.015\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e1.518\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.967-2.383\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e0.070\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003eInvasive depth\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Superficial vs. Muscle\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e0.651\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.256-1.656\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e0.368\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Superficial vs. Visceral\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e0.616\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.332-1.141\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e0.123\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003ePreoperative chemotherapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes vs. No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e0.786\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.379-1.630\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e0.517\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u003cstrong\u003ePostoperative chemotherapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.1944%;\" valign=\"top\" width=\"37.11340206185567%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes vs. No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 11.377%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e0.955\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 19.6071%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e0.616-1.480\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 12.7083%;\" valign=\"top\" width=\"9.278350515463918%\"\u003e\n \u003cp\u003e0.836\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 9.1984%;\" valign=\"top\" width=\"7.216494845360825%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 5.5675%;\" valign=\"top\" width=\"14.43298969072165%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4.4782%;\" valign=\"top\" width=\"8.24742268041237%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eAbbreviation:\u003c/em\u003e\u003c/strong\u003e FNCLCC: French Federation Natinale des centres de Lutte Cotre le Cancer;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eCox regression analyzes were done for all the above data.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Synovial sarcoma, chemotherapy, overall survival, time to recurrence, prognosis","lastPublishedDoi":"10.21203/rs.3.rs-2054776/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-2054776/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eSynovial sarcoma (SS) is an aggressive but chemosensitive soft tissue sarcoma. However, there are scarce data about the benefit of perioperative chemotherapy in high-grade SS patients. This study aimed to explore important prognostic factors and clinical efficacy of perioperative chemotherapy in high-grade SS patients.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eThis study included 143 high-grade SS patients who underwent curative surgery in Shanghai Cancer Center, Fudan University between 2006 and 2020. Univariate and multivariate analyses were performed to identify independent prognostic predictors. The effects of perioperative chemotherapy on overall survival (OS) or time to recurrence (TTR) were evaluated by Kaplan-Meier curves.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eAmong 143 patients, pre- and post-operative chemotherapy were delivered in 17 cases and 88 cases, respectively. Kaplan-Meier curves did not identify obvious differences in OS or TTR concerning perioperative chemotherapy. However, there is a trend towards better OS and TTR in patients receiving preoperative chemotherapy. The corresponding TTR or OS probabilities at 5-year were 49.9%, and 84.4%, respectively in patients with preoperative chemotherapy while 36.2%, and 56.6%, respectively in patients without. Multivariate analyses identified age and tumor size as independent factors for TTR while tumor size and necrosis were independent predictors for worse OS.\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e \u003cp\u003eHigh-grade SS patients might benefit from preoperative chemotherapy but not postoperative chemotherapy. Tumor size, age and necrosis were important factors influencing patients\u0026rsquo; prognosis.\u003c/p\u003e","manuscriptTitle":"Role of perioperative chemotherapy for high-grade synovial sarcoma: a retrospective study of a single Asian cohort in China","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2022-09-20 23:18:13","doi":"10.21203/rs.3.rs-2054776/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"33b77e5b-7856-4238-a895-2ec376794067","owner":[],"postedDate":"September 20th, 2022","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2023-05-22T08:44:19+00:00","versionOfRecord":[],"versionCreatedAt":"2022-09-20 23:18:13","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-2054776","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-2054776","identity":"rs-2054776","version":["v1"]},"buildId":"7rjqhiLT3MXkJMwkYKINL","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}